-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Praesidio Signs Distribution Agreement With Pure Integrative Pharmacy
Praesidio Signs Distribution Agreement With Pure Integrative Pharmacy
VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce that it has signed a distribution agreement for Praesidio Health (Praesidio) products with Pure Integrative Pharmacy (PURE).
"I am excited to announce our first executed distribution agreement in Canada", says CEO Phil Floucault. "The Praesidio team has been working hard to bring our NPN formulations forward and get them into the hands of consumers. Pure Integrative Pharmacy, with their commitment to evidence-based complementary medicines and cutting-edge products, is a perfect fit for Praesidio Health products. This is the first step in delivering on our commitment to our shareholders of having products at market in Q4 2022. We are very excited to be working with the team at PURE and view this contract as the catalyst for expanding our distribution network not only in Canada, but throughout North America."
Pure Integrative Pharmacy includes 17 locations in British Columbia, Canada. Initially founded to challenge the status quo of community pharmacy, PURE works to bridge the gap between conventional and complementary medicine and become an integrative and accessible hub of health for their clients. Focusing on evidence-based efficacy and safety, PURE strives to bring together the best of conventional and complementary medicine to empower customers to take control of their health.
Praesidio is developing natural health products ("NHPs") using an evidence-based process. Pioneering NHPs and therapeutics, Praesidio is actively developing several NHP candidates for utility in a range of conditions, including post-viral exposure prophylaxis, urological, anxiety/stress, immune boosting, and sleep aids. Praesidio has submitted all first round product formulations to Health Canada for review and approval as natural health products.
On Behalf of The Board of Directors
"Phil Floucault"
Phil Floucault
Chief Executive Officer and President
About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is a multidisciplinary cannabis focused producer and product developer with Israeli-based cannabis production farm assets and a Canadian natural health medicine development and production arm. Concurrently focused on initial retail sales in Canada and in becoming a premier cannabis producer offering low-cost domestic Israeli production, the Company aims to commercialize natural health medicines in Canada and to leverage agreements within Israel for import/export opportunities and medicinal marijuana cultivation. For more information visit: .
Contact
Empire Communications Group
+1 (604) 343-2724
info@isracann.com
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements may include, without limitation, statements relating to the Company delivering products to market in Q4 2022 and the Company's plans to expand its distribution network in Canada and North America. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company's documents filed from time to time with the CSE, the British Columbia Securities Commission, the Alberta Securities Commission, and the Ontario Securities Commission. Although Isracann believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Isracann expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce that it has signed a distribution agreement for Praesidio Health (Praesidio) products with Pure Integrative Pharmacy (PURE).
温哥华,不列颠哥伦比亚省,9月2022年1月1日(Global Newswire)--Isracann Biosciences Inc.(CSE:IPOT)(XFRA:A2PT0E)(场外交易:ISCNF)(The“公司“)一家在加拿大拥有天然健康医药部门(Praesidio Health)并在以色列拥有控股公司的多方面组织,高兴地宣布,它已与Pure Integrative Pharmacy(Pure)签署了Praesidio Health(Praesidio)产品的分销协议。
"I am excited to announce our first executed distribution agreement in Canada", says CEO Phil Floucault. "The Praesidio team has been working hard to bring our NPN formulations forward and get them into the hands of consumers. Pure Integrative Pharmacy, with their commitment to evidence-based complementary medicines and cutting-edge products, is a perfect fit for Praesidio Health products. This is the first step in delivering on our commitment to our shareholders of having products at market in Q4 2022. We are very excited to be working with the team at PURE and view this contract as the catalyst for expanding our distribution network not only in Canada, but throughout North America."
首席执行官菲尔·弗洛科说:“我很兴奋地宣布,我们在加拿大签署了第一份经销协议。”Praesidio团队一直在努力将我们的NPN配方推向消费者手中。Pure Integrative Pharmacy致力于以证据为基础的补充药物和尖端产品,非常适合Praesidio保健产品。这是履行我们对股东的承诺的第一步,即2022年第四季度将产品推向市场。我们非常高兴能与PURE团队合作,并将这份合同视为扩大我们不仅在加拿大,而且在整个北美分销网络的催化剂。
Pure Integrative Pharmacy includes 17 locations in British Columbia, Canada. Initially founded to challenge the status quo of community pharmacy, PURE works to bridge the gap between conventional and complementary medicine and become an integrative and accessible hub of health for their clients. Focusing on evidence-based efficacy and safety, PURE strives to bring together the best of conventional and complementary medicine to empower customers to take control of their health.
纯正综合药房在加拿大不列颠哥伦比亚省有17个分店。成立最初是为了挑战社区药房的现状,Pure致力于弥合传统医学和补充医学之间的差距,并成为其客户的综合和可访问的健康中心。专注于循证的疗效和安全性,PURE努力将传统药物和补充药物的最佳结合在一起,使客户能够控制自己的健康。
Praesidio is developing natural health products ("NHPs") using an evidence-based process. Pioneering NHPs and therapeutics, Praesidio is actively developing several NHP candidates for utility in a range of conditions, including post-viral exposure prophylaxis, urological, anxiety/stress, immune boosting, and sleep aids. Praesidio has submitted all first round product formulations to Health Canada for review and approval as natural health products.
Praesidio正在使用循证过程开发天然保健品(NHP)。作为NHP和治疗学的先驱,Praesidio正在积极开发几种NHP候选方案,用于一系列条件,包括病毒暴露后预防、泌尿外科、焦虑/压力、免疫增强和睡眠辅助。Praesidio已将所有第一轮产品配方提交给加拿大卫生部,供审查和批准为天然保健品。
On Behalf of The Board of Directors
我谨代表董事会
"Phil Floucault"
《菲尔·弗洛科》
Phil Floucault
Chief Executive Officer and President
菲尔·弗洛科
首席执行官兼总裁
About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is a multidisciplinary cannabis focused producer and product developer with Israeli-based cannabis production farm assets and a Canadian natural health medicine development and production arm. Concurrently focused on initial retail sales in Canada and in becoming a premier cannabis producer offering low-cost domestic Israeli production, the Company aims to commercialize natural health medicines in Canada and to leverage agreements within Israel for import/export opportunities and medicinal marijuana cultivation. For more information visit: .
Isracann Biosciences公司简介(CSE:IPOT)(XFRA:A2PT0E)(场外交易:ISCNF)
Isracann是一家专注于多学科的大麻生产商和产品开发商,拥有以色列的大麻生产农场资产和加拿大天然保健药物开发和生产部门。该公司同时专注于加拿大的初始零售,并成为提供低成本以色列国内生产的主要大麻生产商,其目标是在加拿大将天然保健药物商业化,并利用以色列境内的协议获得进出口机会和药用大麻种植。有关更多信息,请访问:。
Contact
Empire Communications Group
+1 (604) 343-2724
info@isracann.com
联系方式
帝国通信集团
+1 (604) 343-2724
邮箱:Info@isracann.com
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements may include, without limitation, statements relating to the Company delivering products to market in Q4 2022 and the Company's plans to expand its distribution network in Canada and North America. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company's documents filed from time to time with the CSE, the British Columbia Securities Commission, the Alberta Securities Commission, and the Ontario Securities Commission. Although Isracann believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Isracann expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
前瞻性信息
本新闻稿可能包含前瞻性陈述。前瞻性陈述是指不是历史事实的陈述,一般但并非总是以“预期”、“计划”、“预期”、“相信”、“打算”、“估计”、“项目”、“可能”和类似的表述,或事件或条件“将”、“将”、“可能”、“可能”或“应该”发生。前瞻性陈述可能包括但不限于与公司在2022年第四季度向市场交付产品以及公司在加拿大和北美扩大分销网络的计划有关的陈述。本新闻稿中包含的前瞻性陈述完全受本警告性声明的限制。本新闻稿中的所有前瞻性陈述都是在本新闻稿发布之日作出的。本文中包含的前瞻性陈述一般也会受到假设和风险及不确定因素的影响,这些假设和风险及不确定因素在公司不时提交给CSE、不列颠哥伦比亚省证券委员会、艾伯塔省证券委员会和安大略省证券委员会的文件中有所描述。尽管Isracann认为这些前瞻性陈述中表达的预期是基于合理的假设,但这些陈述并不能保证未来的业绩,实际结果可能与前瞻性陈述中的结果大不相同。Isracann明确表示不会因新信息、未来事件或其他原因而更新或修改任何前瞻性陈述,也不承担任何义务。
The CSE does not accept responsibility for the adequacy or accuracy of this release.
CSE不对本新闻稿的充分性或准确性承担责任。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧